

Supplementary Table S1. Complete Scopus Search Strategy

Database: Scopus

Search date: 30 June 2026

Search field: TITLE-ABS-KEY

Language: English

Document types: Articles and Reviews

Publication year restriction: None

Subject area restriction: None

Complete Scopus search query:

```
TITLE-ABS-KEY (
(
"long-acting antiretroviral*" OR
"long acting antiretroviral*" OR
"long-acting injectable antiretroviral*" OR
"injectable antiretroviral*" OR
"long-acting injectable ART" OR
"injectable ART" OR
"long-acting ART" OR
"long acting ART" OR
"long-acting PrEP" OR
"injectable PrEP" OR
"long-acting cabotegravir" OR
"cabotegravir/rilpivirine" OR
"cabotegravir rilpivirine" OR
"cabotegravir plus rilpivirine" OR
"CAB-LA" OR
"LA-CAB" OR
"CAB/RPV" OR
"long-acting rilpivirine" OR
"long-acting lenacapavir" OR
lenacapavir OR
islatravir OR
"MK-8591"
)
AND
(
HIV OR
HIV-1 OR
"human immunodeficiency virus"
)
)
```

Supplementary Table S2. Thesaurus File Used for Keyword Standardization

Terms with an empty replacement field in the operational VOSviewer thesaurus were excluded from the keyword analysis. Terms not listed in the thesaurus were retained unchanged.

Label (as it appeared in the raw dataset)	Standardized term used in analysis
hiv	hiv
human immunodeficiency virus	hiv
hiv-1	hiv
hiv-1	hiv
hiv-2	hiv
hiv-2	hiv
hiv/aids	hiv
hiv/aids	hiv
hiv & aids	hiv
hiv & aids	hiv
aids	hiv
aids	hiv
hiv infection	hiv
hiv infection	hiv
hiv infections	hiv
hiv infections	hiv
prep	pre-exposure prophylaxis
pre-exposure prophylaxis (prep)	pre-exposure prophylaxis
preexposure prophylaxis	pre-exposure prophylaxis
pre exposure prophylaxis	pre-exposure prophylaxis
hiv prep	pre-exposure prophylaxis
hiv prep	pre-exposure prophylaxis
hiv pre-exposure prophylaxis	pre-exposure prophylaxis
hiv pre-exposure prophylaxis	pre-exposure prophylaxis
hiv preexposure prophylaxis	pre-exposure prophylaxis
hiv preexposure prophylaxis	pre-exposure prophylaxis
art	antiretroviral therapy
antiretroviral therapy (art)	antiretroviral therapy
antiretroviral	antiretroviral therapy
antiretroviral agents	antiretroviral therapy
anti-hiv agents	antiretroviral therapy
antiretroviral drugs	antiretroviral therapy
antiretrovirals	antiretroviral therapy
antiretroviral treatment	antiretroviral therapy
long acting	long-acting
long-acting antiretroviral	long-acting art
long-acting antiretroviral drugs	long-acting art
long-acting antiretroviral therapy	long-acting art
long-acting antiretrovirals	long-acting art
long-acting injectable	long-acting art
long-acting injectables	long-acting art
long-acting injectable art	long-acting art
long-acting injectable antiretroviral	long-acting art
long-acting injectable antiretroviral therapy	long-acting art
long-acting injectable antiretrovirals	long-acting art
long-acting therapy	long-acting art
long-acting injectable prep	long-acting prep
injectable prep	long-acting prep

Label (as it appeared in the raw dataset)	Standardized term used in analysis
injectable prep	long-acting prep
lai-prep	long-acting prep
lai-prep	long-acting prep
cab-la	cabotegravir
long-acting cabotegravir	cabotegravir
long-acting injectable cabotegravir	cabotegravir
cabotegravir-rilpivirine	cabotegravir
cabotegravir/rilpivirine	cabotegravir
cabotegravir plus rilpivirine	cabotegravir
mk-8591	islatravir
islatravir	islatravir
gs-6207	lenacapavir
sunlenca	lenacapavir
msm	men who have sex with men
gay	men who have sex with men
gay and bisexual men	men who have sex with men
sexual minority men	men who have sex with men
transgender	transgender women
adolescent	adolescents
adolescent girls and young women	adolescents
virologic suppression	viral suppression
virological suppression	viral suppression
virologic failure	virological failure
patient preference	patient preferences
preference	patient preferences
preferences	patient preferences
implementation	implementation
implementation science	implementation science
injectable	injectable
clinical trial	<i>Excluded from the keyword analysis</i>
clinical trials	<i>Excluded from the keyword analysis</i>
qualitative	<i>Excluded from the keyword analysis</i>
qualitative research	<i>Excluded from the keyword analysis</i>
qualitative study	<i>Excluded from the keyword analysis</i>
hiv-1 capsid	<i>Excluded from the keyword analysis</i>
hiv-1 capsid	<i>Excluded from the keyword analysis</i>
capsid	<i>Excluded from the keyword analysis</i>
capsid inhibitor	<i>Excluded from the keyword analysis</i>
reverse transcriptase	<i>Excluded from the keyword analysis</i>
reverse transcriptase inhibitors	<i>Excluded from the keyword analysis</i>
nucleoside reverse transcriptase	<i>Excluded from the keyword analysis</i>
nucleoside reverse transcriptase inhibitors	<i>Excluded from the keyword analysis</i>
nucleoside reverse transcriptase translocation inhibitor	<i>Excluded from the keyword analysis</i>
drug-drug interaction	<i>Excluded from the keyword analysis</i>
drug-drug interactions	<i>Excluded from the keyword analysis</i>
women	<i>Excluded from the keyword analysis</i>
pregnancy	<i>Excluded from the keyword analysis</i>
breastfeeding	<i>Excluded from the keyword analysis</i>
africa	<i>Excluded from the keyword analysis</i>
kenya	<i>Excluded from the keyword analysis</i>
south africa	<i>Excluded from the keyword analysis</i>
latin america	<i>Excluded from the keyword analysis</i>

Label (as it appeared in the raw dataset)	Standardized term used in analysis
sub-saharan africa	<i>Excluded from the keyword analysis</i>
uganda	<i>Excluded from the keyword analysis</i>
united states	<i>Excluded from the keyword analysis</i>
europa	<i>Excluded from the keyword analysis</i>
china	<i>Excluded from the keyword analysis</i>
sexual and gender minorities	<i>Excluded from the keyword analysis</i>
cost-effectiveness	<i>Excluded from the keyword analysis</i>
cost-effectiveness analysis	<i>Excluded from the keyword analysis</i>
treatment	<i>Excluded from the keyword analysis</i>
therapy	<i>Excluded from the keyword analysis</i>
safety	<i>Excluded from the keyword analysis</i>
covid-19	<i>Excluded from the keyword analysis</i>
covid-19	<i>Excluded from the keyword analysis</i>
sars-cov-2	<i>Excluded from the keyword analysis</i>
croi	<i>Excluded from the keyword analysis</i>
croi	<i>Excluded from the keyword analysis</i>
hcv	<i>Excluded from the keyword analysis</i>
hepatitis b	<i>Excluded from the keyword analysis</i>
hepatitis b virus	<i>Excluded from the keyword analysis</i>
hepatitis c	<i>Excluded from the keyword analysis</i>
biocatalysis	<i>Excluded from the keyword analysis</i>

Supplementary Table S3. General bibliometric characteristics of the dataset

Description	Results
Timespan	2006-2026
Documents (Scopus)	1,573
Sources (journals)	389
Document types	Articles: 1,242; Reviews: 331
Total citations	29,091
Average citations per document	18.49
Authors	9,712
Average authors per document	10.77
Author's keywords (DE)	2,425
International co-authorship	36.1%


Supplementary Table S4. Top 10 institutions and top 10 corresponding-author countries

Institution	n	Country - corresponding author	n
University of California	180	United States	827
University of Washington	157	United Kingdom	87
ViiV Healthcare	148	Italy	76
University of Nebraska Medical Center	81	South Africa	53
University of Cape Town	76	Spain	47
University of California San Francisco	74	France	43
University of the Witwatersrand	69	China	38
Gilead Sciences	63	Uganda	26
Johns Hopkins University	63	Japan	24
Harvard Medical School	61	Switzerland	24

Supplementary Table S5. Top 20 Most-Cited Documents and Funding Source Classification

#	First author, Journal, Year	Cited by	Trial/Topic	Funding classification
1	Landovitz RJ et al. N Engl J Med. 2021	771	HPTN 083	Public (NIH/NIAID); industry-supplied study product
2	Huffman MA et al. Science. 2019	546	Islatravir synthesis	Industry-funded (Merck)
3	Swindells S et al. N Engl J Med. 2020	519	ATLAS	Industry-funded (ViiV Healthcare)
4	Gandhi RT et al. JAMA. 2023	510	IAS-USA 2022 guideline	Guideline/society publication (IAS-USA)
5	Margolis DA et al. Lancet. 2017	452	LATTE-2	Mixed funding (ViiV/Janssen; NIAID acknowledged)
6	Orkin C et al. N Engl J Med. 2020	419	FLAIR	Industry-funded (ViiV Healthcare)
7	Saag MS et al. JAMA. 2020	414	IAS-USA 2020 guideline	Guideline/society publication (IAS-USA; mixed acknowledgements)
8	Bekker L-G et al. N Engl J Med. 2024	390	PURPOSE 1	Industry-funded (Gilead Sciences)
9	Link JO et al. Nature. 2020	348	Capsid-targeting discovery	Industry-affiliated/mixed (Gilead-led; public grants reported)
10	Overton ET et al. Lancet. 2020	336	ATLAS-2M	Industry-funded (ViiV Healthcare)
11	Segal-Maurer S et al. N Engl J Med. 2022	260	CAPELLA	Industry-funded (Gilead Sciences)
12	Spreeen WR et al. Curr Opin HIV AIDS. 2013	231	Review	Industry-affiliated (ViiV employee; funding not stated)
13	Margolis DM et al. Science. 2016	203	HIV cure/latency review	Public/academic funding (NIH/NIAID; UNC CFAR)
14	Margolis DA et al. Lancet Infect Dis. 2015	199	CAB+RPV induction study	Industry-funded (ViiV/Janssen)
15	Cutrell AG et al. AIDS. 2021	193	Virologic failure predictors	Industry-funded (Janssen/ViiV)
16	Kelley CF et al. N Engl J Med. 2025	191	PURPOSE 2	Industry-funded (Gilead Sciences)
17	Markowitz M et al. Lancet HIV. 2017	186	CAB injection safety	Industry-funded/industry-led (ECLAIR)
18	Bester SM et al. Science. 2020	185	Capsid inhibitor mechanism	Public/academic funding (NIH/NIAID)
19	Menéndez-Arias L et al. Trends Pharmacol Sci. 2022	183	ART review	Mixed funding (industry and Spanish public grants)
20	Van 't Klooster G et al. Antimicrob Agents Chemother. 2010	182	Rilpivirine (TMC278) PK	Industry-affiliated (Janssen programme; funding not stated)

Supplementary Figure S1 Document-level bibliographic coupling network (100 documents, 6 clusters). Node size represents the document's relative weight in the network, colors represent clusters, and link thickness represents the strength of shared references between two documents.



Supplementary Figure S2 Bibliographic co-citation network. Node size represents citation frequency, and colors represent clusters.

